Abacavir Trial for AIDS Dementia Complex
Author Information
Author(s): Bruce J Brew, Mark Halman, Jose Catalan, Ned Sacktor, Richard W Price, Steve Brown, Hamp Atkinson, David B Clifford, David Simpson, Gabriel Torres, Colin Hall, Christopher Power, Karen Marder, Justin C McArthur, William Symonds, Carmen Romero
Primary Institution: National Centre in HIV Epidemiology and Clinical Research, St. Vincent's Hospital, Darlinghurst, Sydney, Australia
Hypothesis
Does adding abacavir to stable background antiretroviral therapy improve outcomes for patients with AIDS dementia complex?
Conclusion
Adding abacavir to stable background therapy did not improve outcomes for patients with AIDS dementia complex.
Supporting Evidence
- The median change in neuropsychological performance was similar in both treatment groups.
- More participants in the abacavir group had undetectable plasma HIV RNA at week 12.
- Two-thirds of participants had baseline resistance to abacavir.
- The study was underpowered due to greater than expected variability in neuropsychological performance.
Takeaway
The study tested if a drug called abacavir could help people with brain problems from HIV, but it didn't make a difference compared to a placebo.
Methodology
Phase III randomized, double-blind placebo-controlled trial with participants receiving either abacavir or placebo for 12 weeks.
Potential Biases
The study was randomized and controlled, minimizing bias, but there were concerns about the stability of participants' conditions at entry.
Limitations
Many participants had baseline resistance to abacavir, and the study was underpowered due to high variability in neuropsychological performance.
Participant Demographics
Participants were HIV-positive adults aged 18 to 65 with mild to moderate AIDS dementia complex.
Statistical Information
P-Value
0.735
Statistical Significance
p = 0.735
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website